Comparative Pharmacology
Head-to-head clinical analysis: EGATEN versus PENTACARINAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EGATEN versus PENTACARINAT.
EGATEN vs PENTACARINAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triclabendazole inhibits tubulin polymerization by binding to the colchicine binding site on beta-tubulin, leading to disruption of microtubule formation and paralysis/death of susceptible parasites, particularly Fasciola species.
Pentamidine is an antiprotozoal agent that interferes with the synthesis of nucleic acids and proteins, possibly through inhibition of dihydrofolate reductase and disruption of polyamine synthesis.
10 mg/kg orally as a single dose, with food; for fascioliasis, 10 mg/kg orally three times daily for 3 days.
4 mg/kg IV once daily for 21 days for Pneumocystis jirovecii pneumonia (PCP) treatment; 300 mg (or 4 mg/kg) via nebulizer once monthly for PCP prophylaxis.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in healthy adults; prolonged to 8-12 hours in severe hepatic impairment. Clinical context: supports once-daily dosing.
Terminal elimination half-life is 3-4 hours in patients with normal renal function, but can be prolonged to 18-24 hours in renal impairment.
Primarily fecal (90% as metabolites); renal excretion of unchanged drug is negligible (<1%).
Renal: 10-20% unchanged; biliary/fecal: minimal; remainder metabolized.
Category C
Category C
Antiprotozoal Agent
Antiprotozoal Agent